Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANK...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EBioMedicine
Auteurs principaux: Widschwendter, Martin, Burnell, Matthew, Fraser, Lindsay, Rosenthal, Adam N., Philpott, Sue, Reisel, Daniel, Dubeau, Louis, Cline, Mark, Pan, Yang, Yi, Ping-Cheng, Gareth Evans, D., Jacobs, Ian J., Menon, Usha, Wood, Charles E., Dougall, William C.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4634624/
https://ncbi.nlm.nih.gov/pubmed/26629528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2015.08.037
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires